전이성 흑색종 암 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Persistence Market Research recently conducted an in-depth analysis of the Metastatic Melanoma Cancer Diagnostics Market, resulting in a comprehensive report that delves extensively into its global landscape. This detailed publication provides valuable insights into the market's dynamics, trends, opportunities, and challenges, offering a thorough overview of its structure. With the support of exclusive data and statistics, the research predicts the anticipated growth trajectory of the Metastatic Melanoma Cancer Diagnostics Market spanning from 2024 to 2033.

The global metastatic melanoma cancer diagnostics market is expected to generate revenue of USD 3.7 billion in 2024. Projected to grow at a compound annual growth rate (CAGR) of 7.8%, the market is anticipated to reach a valuation of USD 7.2 billion by the end of 2033.

Key Insights:

• Metastatic Melanoma Cancer Diagnostics Market Size (2024): USD 3.7 billion
• Projected Market Value (2033):USD 7.2 billion
• Global Market Growth Rate (CAGR 2024-2033):7.8%

Metastatic Melanoma Cancer Diagnostics Market - Report Scope:

Metastatic melanoma cancer diagnostics play a crucial role in the early detection and treatment of melanoma, a serious form of skin cancer. Diagnostics tools and methods include imaging tests, biopsies, molecular tests, and blood tests that help in identifying the spread of melanoma to other parts of the body. The market caters to hospitals, clinics, diagnostic laboratories, and research institutes, offering a range of diagnostic technologies and services. Market growth is driven by increasing incidence rates of melanoma, advancements in diagnostic technologies, and a growing emphasis on early detection and personalized medicine.

Market Growth Drivers:

The global metastatic melanoma cancer diagnostics market is propelled by several key factors, including rising melanoma incidence rates, which necessitate efficient and early diagnostic solutions. Technological advancements in diagnostic tools, such as next-generation sequencing (NGS) and liquid biopsy, enhance the accuracy and speed of melanoma detection, contributing to market expansion. The increasing adoption of personalized medicine and targeted therapies further drives demand for advanced diagnostic methods that can provide detailed genetic and molecular information about melanoma. Additionally, heightened awareness and screening programs for skin cancer encourage early diagnosis, improving treatment outcomes and fueling market growth.

Market Restraints:

Despite promising growth prospects, the metastatic melanoma cancer diagnostics market faces challenges related to high costs and limited accessibility of advanced diagnostic tools in some regions. The high cost of diagnostic procedures and equipment can be a barrier to widespread adoption, particularly in emerging economies with constrained healthcare budgets. Regulatory hurdles and stringent approval processes for new diagnostic technologies can also delay market entry and commercialization. Furthermore, variability in reimbursement policies for diagnostic tests across different regions impacts market growth, requiring manufacturers and healthcare providers to navigate complex regulatory landscapes.

Market Opportunities:

The metastatic melanoma cancer diagnostics market presents significant growth opportunities driven by innovations in diagnostic technologies, expanding healthcare infrastructure, and increasing investment in cancer research. The integration of artificial intelligence (AI) and machine learning (ML) in diagnostic tools enhances accuracy and efficiency, offering new possibilities for early detection and personalized treatment plans. The development of non-invasive and minimally invasive diagnostic methods, such as liquid biopsy, provides safer and more convenient options for patients, broadening the market scope. Strategic partnerships, research collaborations, and investment in emerging markets are essential to capitalize on these opportunities and sustain market leadership.

Competitive Intelligence and Business Strategy:

Leading players in the global metastatic melanoma cancer diagnostics market, including F. Hoffmann-La Roche Ltd., Illumina, Inc., and Agilent Technologies, Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic solutions, including NGS, liquid biopsy, and molecular diagnostics, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, research institutes, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving melanoma diagnostics landscape.

Key Companies Profiled:

• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories, Inc.
• Bio-Rad Laboratories, Inc.
• Guardant Health, Inc.
• Castle Biosciences, Inc.

Key Segments Covered in Metastatic Melanoma Cancer Diagnostics Industry Research

Test:

• Biopsy
• Chest X-ray
• Ultrasound
• CT Scan
• MRI
• PET SCAN

Service Provider:

• Hospitals
• Pathology Laboratories
• Cancer Research Centres

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Disease Epidemiology, by Region
• 4.2. Regulatory Landscape
• 4.3. Test Adoption Rates
• 4.4. Technological Advancements
• 4.5. Reimbursement Scenario
• 4.6. PESTEL Analysis
• 4.7. Porter's Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global Cancer Diagnostics Market Overview
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Test Adoption Rates
  • 5.2.2. Frequency of New Test Launches
  • 5.2.3. Regulatory Scenario
  • 5.2.4. Increasing Number of Cancer Prevention Techniques
  • 5.2.5. Epidemiology of Skin Cancer
  • 5.2.6. Reimbursement Scenario
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Test
  • 6.1.2. By Service Provider
  • 6.1.3. By Country
• 6.2. 2024 Market Scenario

7. Global Metastatic Melanoma Cancer Diagnostics Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Test

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Test, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Test, 2024-2033
  • 8.3.1. Biopsy
    • 8.3.1.1. Local excision/excisional biopsy
    • 8.3.1.2. Punch biopsy
    • 8.3.1.3. Shave biopsy
    • 8.3.1.4. Fine needle aspiration (FNA) biopsy
    • 8.3.1.5. Sentinel lymph node biopsy
  • 8.3.2. Chest X-ray
  • 8.3.3. Ultrasound
  • 8.3.4. CT Scan
  • 8.3.5. MRI
  • 8.3.6. PET SCAN
• 8.4. Market Attractiveness Analysis By Test

9. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Service Provider

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis, By Service Provider, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Service Provider, 2024-2033
  • 9.3.1. Hospitals
  • 9.3.2. Pathology Laboratories
  • 9.3.3. Cancer Research Centers
• 9.4. Market Attractiveness Analysis By Service Provider

10. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Region, 2024-2033
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. East Asia
  • 10.3.5. South Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Test
  • 11.3.3. By Service Provider
• 11.4. Market Attractiveness Analysis
  • 11.4.1. By Country
  • 11.4.2. By Test
  • 11.4.3. By Service Provider
• 11.5. Market Trends
• 11.6. Drivers and Restraints - Impact Analysis
• 11.7. Country Level Analysis & Forecast
  • 11.7.1. U.S. Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 11.7.1.1. Introduction
    • 11.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 11.7.1.2.1. By Test
      • 11.7.1.2.2. By Service Provider
  • 11.7.2. Canada Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 11.7.2.1. Introduction
    • 11.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 11.7.2.2.1. By Test
      • 11.7.2.2.2. By Service Provider

12. Latin America Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 12.3.1. By Country
    • 12.3.1.1. Mexico
    • 12.3.1.2. Brazil
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
  • 12.3.2. By Test
  • 12.3.3. By Service Provider
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Test
  • 12.4.3. By Service Provider
• 12.5. Market Trends
• 12.6. Drivers and Restraints - Impact Analysis
• 12.7. Country Level Analysis & Forecast
  • 12.7.1. Mexico Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 12.7.1.1. Introduction
    • 12.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.7.1.2.1. By Test
      • 12.7.1.2.2. By Service Provider
  • 12.7.2. Brazil Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 12.7.2.1. Introduction
    • 12.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.7.2.2.1. By Test
      • 12.7.2.2.2. By Service Provider
  • 12.7.3. Argentina Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 12.7.3.1. Introduction
    • 12.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 12.7.3.2.1. By Test
      • 12.7.3.2.2. By Service Provider

13. Europe Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. Italy
    • 13.3.1.3. France
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. BENELUX
    • 13.3.1.7. Russia
    • 13.3.1.8. Rest of Europe
  • 13.3.2. By Test
  • 13.3.3. By Service Provider
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Test
  • 13.4.3. By Service Provider
• 13.5. Market Trends
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Country Level Analysis & Forecast
  • 13.7.1. Germany Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.1.1. Introduction
    • 13.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.1.2.1. By Test
      • 13.7.1.2.2. By Service Provider
  • 13.7.2. Italy Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.2.1. Introduction
    • 13.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.2.2.1. By Test
      • 13.7.2.2.2. By Service Provider
  • 13.7.3. France Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.3.1. Introduction
    • 13.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.3.2.1. By Test
      • 13.7.3.2.2. By Service Provider
  • 13.7.4. U.K. Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.4.1. Introduction
    • 13.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.4.2.1. By Test
      • 13.7.4.2.2. By Service Provider
  • 13.7.5. Spain Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.5.1. Introduction
    • 13.7.5.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.5.2.1. By Test
      • 13.7.5.2.2. By Service Provider
  • 13.7.6. BENELUX Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.6.1. Introduction
    • 13.7.6.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.6.2.1. By Test
      • 13.7.6.2.2. By Service Provider
  • 13.7.7. Russia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.7.1. Introduction
    • 13.7.7.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.7.2.1. By Test
      • 13.7.7.2.2. By Service Provider

14. East Asia Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. China
    • 14.3.1.2. Japan
    • 14.3.1.3. South Korea
  • 14.3.2. By Test
  • 14.3.3. By Service Provider
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Test
  • 14.4.3. By Service Provider
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Country Level Analysis & Forecast
  • 14.7.1. China Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 14.7.1.1. Introduction
    • 14.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.1.2.1. By Test
      • 14.7.1.2.2. By Service Provider
  • 14.7.2. Japan Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 14.7.2.1. Introduction
    • 14.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.2.2.1. By Test
      • 14.7.2.2.2. By Service Provider
  • 14.7.3. South Korea Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 14.7.3.1. Introduction
    • 14.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.3.2.1. By Test
      • 14.7.3.2.2. By Service Provider

15. South Asia Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. India
    • 15.3.1.2. Indonesia
    • 15.3.1.3. Malaysia
    • 15.3.1.4. Thailand
    • 15.3.1.5. Rest of South Asia
  • 15.3.2. By Test
  • 15.3.3. By Service Provider
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Test
  • 15.4.3. By Service Provider
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Country Level Analysis & Forecast
  • 15.7.1. India Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.1.1. Introduction
    • 15.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.1.2.1. By Test
      • 15.7.1.2.2. By Service Provider
  • 15.7.2. Indonesia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.2.1. Introduction
    • 15.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.2.2.1. By Test
      • 15.7.2.2.2. By Service Provider
  • 15.7.3. Malaysia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.3.1. Introduction
    • 15.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.3.2.1. By Test
      • 15.7.3.2.2. By Service Provider
  • 15.7.4. Thailand Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.4.1. Introduction
    • 15.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.4.2.1. By Test
      • 15.7.4.2.2. By Service Provider

16. Oceania Metastatic Melanoma Cancer Diagnostics Market 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Test
  • 16.3.3. By Service Provider
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Test
  • 16.4.3. By Service Provider
• 16.5. Key Market Participants - Intensity Mapping
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Country Level Analysis & Forecast
  • 16.7.1. Australia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 16.7.1.1. Introduction
    • 16.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.1.2.1. By Test
      • 16.7.1.2.2. By Service Provider
  • 16.7.2. New Zealand Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 16.7.2.1. Introduction
    • 16.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.2.2.1. By Test
      • 16.7.2.2.2. By Service Provider

17. Middle East and Africa (MEA) Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Turkey
    • 17.3.1.3. North Africa
    • 17.3.1.4. South Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Test
  • 17.3.3. By Service Provider
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Test
  • 17.4.3. By Service Provider
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Country Level Analysis & Forecast
  • 17.7.1. GCC Countries Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.1.1. Introduction
    • 17.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.1.2.1. By Test
      • 17.7.1.2.2. By Service Provider
  • 17.7.2. Turkey Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.2.1. Introduction
    • 17.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.2.2.1. By Test
      • 17.7.2.2.2. By Service Provider
  • 17.7.3. South Africa Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.3.1. Introduction
    • 17.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.3.2.1. By Test
      • 17.7.3.2.2. By Service Provider
  • 17.7.4. North Africa Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.4.1. Introduction
    • 17.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.4.2.1. By Test
      • 17.7.4.2.2. By Service Provider

18. Competition Analysis

• 18.1. Competition Dashboard
• 18.2. Competition Benchmarking
• 18.3. Competition Deep Dive
  • 18.3.1. Amgen Inc
    • 18.3.1.1. Overview
    • 18.3.1.2. Product Portfolio
    • 18.3.1.3. Sales Footprint
    • 18.3.1.4. Strategy Overview
  • 18.3.2. Abbott Laboratories
    • 18.3.2.1. Overview
    • 18.3.2.2. Product Portfolio
    • 18.3.2.3. Sales Footprint
    • 18.3.2.4. Strategy Overview
  • 18.3.3. Bristol-Myers Squibb
    • 18.3.3.1. Overview
    • 18.3.3.2. Product Portfolio
    • 18.3.3.3. Sales Footprint
    • 18.3.3.4. Strategy Overview
  • 18.3.4. Novartis AG
    • 18.3.4.1. Overview
    • 18.3.4.2. Product Portfolio
    • 18.3.4.3. Sales Footprint
    • 18.3.4.4. Strategy Overview
  • 18.3.5. F-Hoffmann-La Roche Ltd
    • 18.3.5.1. Overview
    • 18.3.5.2. Product Portfolio
    • 18.3.5.3. Sales Footprint
    • 18.3.5.4. Strategy Overview
  • 18.3.6. Biomerieux
    • 18.3.6.1. Overview
    • 18.3.6.2. Product Portfolio
    • 18.3.6.3. Sales Footprint
    • 18.3.6.4. Strategy Overview
  • 18.3.7. Quest diagnostics
    • 18.3.7.1. Overview
    • 18.3.7.2. Product Portfolio
    • 18.3.7.3. Sales Footprint
    • 18.3.7.4. Strategy Overview
  • 18.3.8. Agilent Technologies Inc
    • 18.3.8.1. Overview
    • 18.3.8.2. Product Portfolio
    • 18.3.8.3. Sales Footprint
    • 18.3.8.4. Strategy Overview
  • 18.3.9. Myriad Genetics Inc
    • 18.3.9.1. Overview
    • 18.3.9.2. Product Portfolio
    • 18.3.9.3. Sales Footprint
    • 18.3.9.4. Strategy Overview
  • 18.3.10. Qiagen
    • 18.3.10.1. Overview
    • 18.3.10.2. Product Portfolio
    • 18.3.10.3. Sales Footprint
    • 18.3.10.4. Strategy Overview

19. Assumptions and Acronyms Used

20. Research Methodology